Docon Sells 9.9% Stake in Thyrocare for Rs 986 Crore

Docon Technologies, a key promoter of Thyrocare Technologies Ltd, has divested a substantial 9.9% stake in the diagnostics firm, raising Rs 986 crore in the process. This transaction took place through multiple bulk and block deals conducted on both the National Stock Exchange (NSE) and the Bombay Stock Exchange (BSE) on Thursday.

Transaction Details and Market Impact

The stake sale involved the offloading of 1,57,69,696 equity shares. A significant portion of these shares, over 1.31 crore, were sold through block deals, while 10 lakh shares were traded via bulk deals on the NSE. An additional 16.01 lakh shares were sold through a bulk deal on the BSE. The shares were priced in the range of Rs 624 to Rs 631.71 each, culminating in a total transaction value of Rs 985.86 crore.

Following the sale, Docon's ownership in Thyrocare Technologies has decreased from 60.92% to 51.02%. The market responded positively to the news, with Thyrocare's shares rising nearly 3% to Rs 621.95 on the NSE and over 2% to Rs 622 on the BSE the day after the transaction.

Investor Participation

The sale attracted a range of institutional and global investors. Among the buyers were prominent mutual funds such as HSBC Mutual Fund, DSP Mutual Fund, ICICI Prudential Mutual Fund, Aditya Birla Sun Life Mutual Fund, WhiteOak Capital Mutual Fund, and ITI Mutual Fund. Insurance companies like Kotak Mahindra Life Insurance Company and Tata AIA Life Insurance also participated. Additionally, global financial entities including Morgan Stanley, Citigroup Global Markets, HBM Healthcare Investments (Cayman), and the sovereign wealth fund Kuwait Investment Authority acquired shares through block deals on the NSE.

Background and Previous Transactions

This recent divestment follows Docon's earlier sale of a 10% stake in Thyrocare for Rs 667 crore in October of the previous year. These transactions are part of a broader trend of stake rebalancing by promoters in the diagnostics sector, which has seen increased investor interest due to the growing demand for healthcare services.

Thyrocare Technologies, a prominent player in the diagnostics industry, continues to be a focal point for investors looking to capitalize on the expanding healthcare market in India. The company's strategic positioning and consistent performance have made its shares attractive to both domestic and international investors.